Holen Sie sich die Stockscreener-App
1.42
73.33%
-3.905
Handel nachbörslich:
1.61
0.19
+13.38%
Schlusskurs vom Vortag:
$5.325
Offen:
$1.445
24-Stunden-Volumen:
22.02M
Relative Volume:
23.93
Marktkapitalisierung:
$84.79M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-44.80M
KGV:
-1.8933
EPS:
-0.75
Netto-Cashflow:
$-30.67M
1W Leistung:
-77.32%
1M Leistung:
-76.57%
6M Leistung:
-72.85%
1J Leistung:
-65.78%
1-Tages-Spanne:
$1.14
$1.78
1-Wochen-Bereich:
$1.14
$6.73
52-Wochen-Spanne:
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Firmenname
Aldeyra Therapeutics Inc
Sektor
Branche
Telefon
781-761-4904
Adresse
131 HARTWELL AVENUE, LEXINGTON, MA
Vergleichen Sie ALDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
1.42 | 84.79M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-03 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-04-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-04-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-02-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-10-30 | Eingeleitet | Jefferies | Buy |
| 2020-10-16 | Eingeleitet | BTIG Research | Buy |
| 2020-09-22 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-05-12 | Eingeleitet | Oppenheimer | Outperform |
| 2018-12-04 | Eingeleitet | Citigroup | Buy |
| 2018-09-26 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Eingeleitet | Janney | Buy |
| 2018-01-26 | Eingeleitet | Seaport Global Securities | Buy |
| 2016-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-07-01 | Eingeleitet | Stifel | Buy |
| 2015-07-01 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-03-25 | Eingeleitet | Chardan Capital Markets | Buy |
| 2015-03-20 | Bestätigt | H.C. Wainwright | Buy |
| 2014-11-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2014-06-19 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Aldeyra Therapeutics Inc Aktie (ALDX) Neueste Nachrichten
Aldeyra Therapeutics Receives FDA Complete Response Letter - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra - Bluefield Daily Telegraph
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. – ALDX - TradingView
Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter - MSN
Biotech Shake-Up: Aldeyra Therapeutics & Others Feel The Heat - Finimize
Top Midday Decliners - MarketScreener
11 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
US FDA declines to approve Aldeyra's eye disease drug - Reuters
Crude Oil Dips 7%; ISM Services PMI Falls In March - Benzinga
ALDX BREAKING NEWS: Aldeyra Therapeutics, Inc. 75% Stock - GlobeNewswire
Small cap wrap: Excellon Resources, Trust Stamp, Aldeyra Therapeutics... - Proactive financial news
BREAKING: Block & Leviton Investigating Aldeyra Therapeutics (ALDX) For Securities Fraud ... - Bluefield Daily Telegraph
BREAKING: Block & Leviton Investigating Aldeyra - GlobeNewswire
BREAKING: Block & Leviton Investigating Aldeyra Therapeutics (ALDX) For Securities Fraud After Shares Fall Nearly 75%; Investors Encouraged to Contact the Firm - TradingView
Aldeyra Therapeutics tanks as FDA rejects investigational dry eye disease therapy - Proactive financial news
U.S. FDA declines to approve Aldeyra’s eye disease drug - PharmaLive
US FDA declines to approve Aldeyra’s eye disease drug - The Mighty 790 KFGO
Aldeyra Stock Slumps After FDA Says Investigational Drug For Dry Eyes Treatment Failed To Demonstrate Efficacy – Retail Stays Optimistic - MSN
Dow Tumbles Over 1,100 Points; US Initial Jobless Claims Fall - Benzinga
FDA Rejects Aldeyra's Reproxalap For Dry Eye Disease Again, Citing Efficacy Concerns - Benzinga
FDA issues Complete Response Letter to Aldeyra Therapeutics for resubmitted New Drug Application of reproxalap - Ophthalmology Times
Aldeyra Therapeutics Gets US FDA Letter for Resubmission of New Drug Application for Eye Disease TreatmentShares Slump Pre-Bell - MarketScreener
Aldeyra Therapeutics stock tumbles after FDA setback - Investing.com India
Aldeyra Therapeutics stock tumbles after FDA setback By Investing.com - Investing.com Canada
Aldeyra Therapeutics (ALDX) Plummets 74% After FDA Rejection - GuruFocus
Aldeyra’s dry eye drug suffers second FDA rejection, but imminent data spur hope of fast recovery - Fierce Biotech
Aldeyra stock tumbles as FDA snubs lead drug (ALDX:NASDAQ) - Seeking Alpha
Aldeyra Therapeutics sets sights on mid-2025 for NDA resubmission - Investing.com
Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye Disease - MarketScreener
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
FDA Denial Forces Aldeyra Back to Trials: Key Details on $101M Cash Position and 2025 Resubmission Plan - Stock Titan
Does Candel Therapeutics Inc (NASDAQ: CADL) Still Need To Convince Analysts? - Stocks Register
Does QXO Inc (NYSE: QXO) Still Look Hot This Week? - Stocks Register
FDA Action Alert: Amgen, Aldeyra and Argenx - BioSpace
SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Raymond James Financial Inc. Invests $3.63 Million in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Trend Tracker for (ALDX) - news.stocktradersdaily.com
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Passes Above 50-Day Moving Average – Here’s Why - Defense World
SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALDX - Business Wire
BTIG maintains Aldeyra stock Buy rating, $11 target By Investing.com - Investing.com Canada
Aldeyra Therapeutics Beats Investor Suit Over Eye Drug Misses - Bloomberg Law News
Aldeyra Therapeutics: Buy Rating Affirmed on Promising Reproxalap and Strategic RASP Market Expansion - TipRanks
(ALDX) On The My Stocks Page - Stock Traders Daily
Biotech Wins Dismissal Of Investor Fraud Claims - Law360
ALDX stock touches 52-week high at $6.93 amid robust gains - Investing.com Australia
ALDX stock touches 52-week high at $6.93 amid robust gains By Investing.com - Investing.com South Africa
Tech Stocks Defying Market Volatility: Meet the Pioneers of Tomorrow’s Economy - DSA
High Growth Tech Stocks To Watch In The US March 2025 - Simply Wall St
Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference - Business Wire
Finanzdaten der Aldeyra Therapeutics Inc-Aktie (ALDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):